irblog.prnewswire.com

NCCN Guidelines Designate Decipher Prostate as "Recommended" for Men with Adverse Pathology after Radical Prostatectomy

SAN DIEGO, March 24, 2020 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today ...
irblog.prnewswire.com

Decipher Biosciences Announces Publication of a Prospective Clinical Study Demonstrating that the Use of Decipher Prostate RP Guides Post-Operative Management Decisions and ...

SAN DIEGO, Dec. 16, 2019 /PRNewswire/ -- Decipher Biosciences, a commercial stage precision oncology company initially focused on urologic cancers, today announced that recent findings from a ...
Medscape

To What End? Decipher Tells Prostate Cancer Metastasis Risk

The Decipher (GenomeDX Biosciences) test differentiates men at higher risk for prostate cancer metastasis after prostatectomy from those at lower risk and adds prognostic value in comparison with ...
Medscape

Decipher Scores Help Predict Upgrade on PCa Active Surveillance

Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...
Nature

Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients

Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...
Business Wire

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the company’s Decipher GRID database could help ...